Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537194 | 0.92 | HTR7 (0.46) | HTR7ALDH1A1HTR1BKDM4ESMN1; SMN2 | |
| SCHEMBL2068329 | 0.81 | SMN1; SMN2 (0.40) | HTR7ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL11375442 | 0.80 | CYP1A2 (0.43) | ALDH1A1DRD2SMN1; SMN2LTA4H | |
| SCHEMBL314855 | 0.78 | CA1 (0.39) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9327083 | 0.76 | CA1 (0.38) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30862623 | 0.75 | HTR7 (0.77) | HTR7ALDH1A1HTR1BDRD2DRD1 | |
| SCHEMBL2456684 | 0.75 | HTR7 (0.77) | HTR7ALDH1A1HTR1BDRD2DRD1 | |
| SCHEMBL20797097 | 0.75 | HTR7 (0.51) | HTR7ALDH1A1HTR1BDRD2DRD1 | |
| SCHEMBL123985 | 0.74 | CA1 (0.48) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7618492 | 0.74 | ALDH1A1 (0.81) | HTR7ALDH1A1HTR1BDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | claimed |
| US-20130267496-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-10-10 | — | — | US | claimed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| JP-4377942-B2 | — | — | 2009-12-02 | — | — | JP | claimed |
| JP-2008531599-A | — | — | 2008-08-14 | — | — | JP | claimed |
| EP-1856057-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | Serenex, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006091963-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2716157-B1 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-8450321-B2 | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR7 2603/4885ALDH1A1 4166/4885HTR1B 4059/4885 |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR7 2603/4885ALDH1A1 4166/4885HTR1B 4059/4885 |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR7 2603/4885ALDH1A1 4166/4885HTR1B 4059/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR7 2603/4885ALDH1A1 4166/4885HTR1B 4059/4885 |
| US-20130267496-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR7 2603/4885ALDH1A1 4166/4885HTR1B 4059/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR7 2603/4885ALDH1A1 4166/4885HTR1B 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.